Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $7.43 Consensus Target Price from Brokerages

Trevi Therapeutics, Inc. (NASDAQ:TRVI) has earned a consensus rating of “Buy” from the nine research firms that are currently covering the firm, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $7.43.

Several equities analysts have weighed in on the company. Needham & Company LLC reissued a “buy” rating and set a $8.00 price objective on shares of Trevi Therapeutics in a report on Friday, November 8th. Leerink Partners started coverage on Trevi Therapeutics in a report on Monday, September 9th. They issued an “outperform” rating and a $7.00 price target for the company. EF Hutton Acquisition Co. I raised Trevi Therapeutics to a “strong-buy” rating in a report on Monday, August 19th. Leerink Partnrs raised Trevi Therapeutics to a “strong-buy” rating in a report on Monday, September 9th. Finally, B. Riley reaffirmed a “buy” rating and issued a $6.00 price target on shares of Trevi Therapeutics in a report on Monday, October 7th.

Insider Buying and Selling at Trevi Therapeutics

In other Trevi Therapeutics news, CEO Jennifer L. Good sold 10,981 shares of Trevi Therapeutics stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $3.02, for a total transaction of $33,162.62. Following the sale, the chief executive officer now directly owns 213,313 shares of the company’s stock, valued at approximately $644,205.26. The trade was a 4.90 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last three months, insiders have sold 21,595 shares of company stock valued at $64,886. 24.37% of the stock is currently owned by corporate insiders.

Institutional Trading of Trevi Therapeutics

Several large investors have recently bought and sold shares of TRVI. BNP Paribas Financial Markets lifted its holdings in shares of Trevi Therapeutics by 130.9% during the third quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock valued at $40,000 after purchasing an additional 6,764 shares during the last quarter. Price T Rowe Associates Inc. MD purchased a new position in shares of Trevi Therapeutics during the first quarter valued at approximately $47,000. Hsbc Holdings PLC purchased a new position in shares of Trevi Therapeutics during the second quarter valued at approximately $61,000. Intech Investment Management LLC purchased a new position in Trevi Therapeutics in the 3rd quarter worth approximately $63,000. Finally, The Manufacturers Life Insurance Company raised its holdings in Trevi Therapeutics by 87.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company’s stock worth $73,000 after acquiring an additional 11,450 shares during the last quarter. 95.76% of the stock is owned by institutional investors.

Trevi Therapeutics Stock Down 3.8 %

Shares of Trevi Therapeutics stock opened at $2.75 on Wednesday. The company has a market cap of $211.38 million, a PE ratio of -6.27 and a beta of 1.01. Trevi Therapeutics has a 52 week low of $0.97 and a 52 week high of $4.00. The business has a 50 day moving average price of $3.14 and a 200-day moving average price of $2.91.

Trevi Therapeutics (NASDAQ:TRVI) last released its earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). During the same quarter in the prior year, the company earned ($0.08) earnings per share. As a group, research analysts anticipate that Trevi Therapeutics will post -0.49 EPS for the current year.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.